Skip to main content
. 2014 Mar 15;28(4):275–281. doi: 10.7555/JBR.28.20120075

Fig. 2. Developmental defects caused by tunicamycin (TM) were rescued with the injection of IRE1αMO and xXBP1(C) MO.

Fig. 2

A: control MO injected embryos at stage 18. B: embryos treated with 2 μg/mL TM at stage 18. C: embryos treated with 2 μg/mL TM and injected with 50 ng IRE1αMO at stage 18. D: embryos treated with 2 μg/mL TM and injected with 50 ng IRE1βMO at stage 18. E: rescue effect on XBP1 splicing. TM treatment led to an increase of xXBP1(C) while TM treatment together with xIRE1α MO injection rescued the change in embryos at stage 11. F: control MO injected embryos at stage 32. G: embryos treated with 2 μg/mL TM at stage 32. H: embryos treated with 2 μg/mL TM and injected with 50 ng IRE1αMO at stage 32. I: embryos treated with 2 μg/mL TM and injected with 50 ng XBP1(C) MO at stage 32. RT-: no-reverse transcriptase control.